IS4871A - Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) - Google Patents

Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Info

Publication number: IS4871A
Authority: IS; Iceland
Prior art keywords: pde; phosphodiesterase; tnf; inhibitors; established
Prior art date: 1996-05-03

Application number

IS4871A

Other languages

English (en)

Inventor

Marfat Anthony

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-03

Filing date

1998-10-16

Publication date

1998-10-16

1998-10-16 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1998-10-16 Publication of IS4871A publication Critical patent/IS4871A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Obesity (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IS4871A 1996-05-03 1998-10-16 Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) IS4871A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1686196P	1996-05-03	1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en)	1996-05-03	1997-04-01	Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number	Publication Date
IS4871A true IS4871A (is)	1998-10-16

Family

ID=21779401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4871A IS4871A (is)	1996-05-03	1998-10-16	Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Country Status (41)

Country	Link
US (2)	US6211222B1 (is)
EP (1)	EP0912521B1 (is)
JP (1)	JP3148254B2 (is)
KR (1)	KR100339935B1 (is)
CN (2)	CN1112359C (is)
AP (4)	AP2001002304A0 (is)
AR (1)	AR006906A1 (is)
AT (1)	ATE292626T1 (is)
AU (1)	AU725576B2 (is)
BG (1)	BG64211B1 (is)
BR (1)	BR9709051A (is)
CA (2)	CA2389918A1 (is)
CO (1)	CO4650038A1 (is)
CZ (1)	CZ292825B6 (is)
DE (1)	DE69732966T2 (is)
DZ (1)	DZ2217A1 (is)
EA (1)	EA002272B1 (is)
ES (1)	ES2238079T3 (is)
GT (1)	GT199700043A (is)
HN (1)	HN1997000046A (is)
HR (1)	HRP970227B1 (is)
HU (1)	HUP9902459A3 (is)
ID (1)	ID16856A (is)
IL (2)	IL152083A0 (is)
IS (1)	IS4871A (is)
MA (1)	MA24158A1 (is)
MY (1)	MY132499A (is)
NO (1)	NO312959B1 (is)
NZ (1)	NZ332240A (is)
OA (1)	OA10904A (is)
PE (1)	PE64598A1 (is)
PL (1)	PL329836A1 (is)
SK (1)	SK148298A3 (is)
TN (1)	TNSN97070A1 (is)
TR (1)	TR199802202T2 (is)
TW (1)	TW449585B (is)
UA (1)	UA65536C2 (is)
UY (1)	UY24532A1 (is)
WO (1)	WO1997042174A1 (is)
YU (1)	YU16397A (is)
ZA (1)	ZA973804B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6005118A (en) *	1996-05-03	1999-12-21	Caron; Stephane	Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
AP2001002304A0 (en) *	1996-05-03	2001-12-31	Pfizer	Substituted indazole derivatives and related compounds
EP0934307B1 (en)	1996-06-19	2011-04-27	Aventis Pharma Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ES2172882T3 (es) *	1997-05-08	2002-10-01	Pfizer Prod Inc	Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
CN1281441A (zh) *	1997-11-04	2001-01-24	辉瑞产品公司	以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物
BR9813926A (pt) *	1997-11-04	2000-09-19	Pfizer Prod Inc	Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
IL126745A (en) *	1997-11-04	2003-09-17	Pfizer Prod Inc	Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
IL132407A0 (en) *	1998-10-21	2001-03-19	Pfizer Prod Inc	Method for treating congestive heart failure
JP2000198734A (ja) *	1998-12-30	2000-07-18	Pfizer Inc	胃運動性減弱および関連疾患の治療のための運動性増強薬
US6303782B1 (en) *	1999-04-20	2001-10-16	Pfizer Inc	Process for preparing benzylnitriles
EP1244649B1 (en) *	1999-12-23	2005-03-02	Icos Corporation	Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en)	1999-12-23	2002-03-26	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US7211594B2 (en) *	2000-07-31	2007-05-01	Signal Pharmaceuticals, Llc	Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en)	2000-08-11	2005-10-11	Applied Research Systems Ars Holding N.V.	Methods of inducing ovulation
DK1463493T3 (da)	2001-12-14	2008-02-04	Serono Lab	Fremgangsmåder til at inducere æglösning ved anvendelse af en ikke polypeptid-cAMP-niveaumodulator
US20040034084A1 (en) *	2002-05-24	2004-02-19	Celgene Corporation	Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) *	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) *	2002-12-31	2005-01-27	Zeldis Jerome B.	Drug-coated stents and methods of use therefor
DE10318610A1 (de)	2003-04-24	2004-11-11	Elbion Ag	7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en)	2004-10-26	2009-10-13	Wyeth	Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) *	2005-03-23	2007-01-04	Bhagwat Shripad S	Methods for treating or preventing acute myelogenous leukemia
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
MX2008013597A (es) *	2006-04-21	2009-01-16	Centocor Inc	Antagonistas del ligado 13 de quimiocina de motivo cxc (cxcl13) y su uso para el tratamiento de enfermedades inflamatorias.
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
SG11202004105TA (en)	2017-11-06	2020-06-29	Rapt Therapeutics Inc	Anticancer agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994890A (en) *	1974-01-31	1976-11-30	Chugai Seiyaku Kabushiki Kaisha	1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) *	1979-10-09	1981-05-14	Konishiroku Photo Ind Co Ltd	Direct positive image forming method
GB8707051D0 (en) *	1986-04-15	1987-04-29	Ici America Inc	Heterocyclic carboxamides
JP2525286B2 (ja) *	1990-11-26	1996-08-14	日本原子力研究所	超耐熱性炭化ケイ素繊維の製造方法
TW223004B (is) *	1991-11-25	1994-05-01	Sumitomo Chemical Co
WO1993018008A1 (en) *	1992-03-09	1993-09-16	Zeneca Limited	Novel arylindazoles and their use as herbicides
US5444038A (en) *	1992-03-09	1995-08-22	Zeneca Limited	Arylindazoles and their use as herbicides
EP0633776B1 (en) *	1992-04-02	2001-05-09	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) *	1993-09-14	1996-09-10	Sterling Winthrop Inc.	Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) *	1993-12-07	1995-08-08	Miles Inc.	Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
NZ292991A (en) *	1994-10-20	1999-02-25	Pfizer	Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
AU709965B2 (en) *	1994-10-21	1999-09-09	Elisha Holding Llc	Corrosion preventing buffersystem for metal products
AP2001002304A0 (en) *	1996-05-03	2001-12-31	Pfizer	Substituted indazole derivatives and related compounds
ES2172882T3 (es) *	1997-05-08	2002-10-01	Pfizer Prod Inc	Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.

1996
- 1996-05-03 AP AP2001002304A patent/AP2001002304A0/xx unknown
- 1996-05-03 AP APAP/P/2001/002294A patent/AP1147A/en active
1997
- 1997-01-04 UA UA98105434A patent/UA65536C2/uk unknown
- 1997-04-01 JP JP53967097A patent/JP3148254B2/ja not_active Expired - Fee Related
- 1997-04-01 CZ CZ19983492A patent/CZ292825B6/cs not_active IP Right Cessation
- 1997-04-01 WO PCT/IB1997/000323 patent/WO1997042174A1/en not_active Ceased
- 1997-04-01 NZ NZ332240A patent/NZ332240A/xx unknown
- 1997-04-01 CA CA002389918A patent/CA2389918A1/en not_active Abandoned
- 1997-04-01 PL PL97329836A patent/PL329836A1/xx unknown
- 1997-04-01 TR TR1998/02202T patent/TR199802202T2/xx unknown
- 1997-04-01 EA EA199800882A patent/EA002272B1/ru not_active IP Right Cessation
- 1997-04-01 AP APAP/P/2001/002304A patent/AP0102304A0/en unknown
- 1997-04-01 DE DE69732966T patent/DE69732966T2/de not_active Expired - Fee Related
- 1997-04-01 EP EP97907247A patent/EP0912521B1/en not_active Expired - Lifetime
- 1997-04-01 CN CN97194356A patent/CN1112359C/zh not_active Expired - Fee Related
- 1997-04-01 AT AT97907247T patent/ATE292626T1/de not_active IP Right Cessation
- 1997-04-01 ES ES97907247T patent/ES2238079T3/es not_active Expired - Lifetime
- 1997-04-01 KR KR1019980708867A patent/KR100339935B1/ko not_active Expired - Fee Related
- 1997-04-01 CA CA002252982A patent/CA2252982C/en not_active Expired - Fee Related
- 1997-04-01 TW TW086104176A patent/TW449585B/zh active
- 1997-04-01 AU AU19373/97A patent/AU725576B2/en not_active Ceased
- 1997-04-01 HU HU9902459A patent/HUP9902459A3/hu unknown
- 1997-04-01 BR BR9709051A patent/BR9709051A/pt active Search and Examination
- 1997-04-01 IL IL15208397A patent/IL152083A0/xx unknown
- 1997-04-01 SK SK1482-98A patent/SK148298A3/sk unknown
- 1997-04-01 IL IL12654797A patent/IL126547A/xx not_active IP Right Cessation
- 1997-04-04 HN HN1997000046A patent/HN1997000046A/es unknown
- 1997-04-10 GT GT199700043A patent/GT199700043A/es unknown
- 1997-04-28 UY UY24532A patent/UY24532A1/es not_active IP Right Cessation
- 1997-04-29 YU YU16397A patent/YU16397A/sh unknown
- 1997-04-29 AR ARP970101769A patent/AR006906A1/es not_active Application Discontinuation
- 1997-04-30 TN TNTNSN97070A patent/TNSN97070A1/fr unknown
- 1997-04-30 DZ DZ970064A patent/DZ2217A1/fr active
- 1997-04-30 PE PE1997000330A patent/PE64598A1/es not_active Application Discontinuation
- 1997-04-30 MA MA24577A patent/MA24158A1/fr unknown
- 1997-04-30 AP APAP/P/1997/000975A patent/AP1146A/en active
- 1997-05-02 HR HR970227A patent/HRP970227B1/xx not_active IP Right Cessation
- 1997-05-02 ID IDP971466A patent/ID16856A/id unknown
- 1997-05-02 ZA ZA973804A patent/ZA973804B/xx unknown
- 1997-05-02 MY MYPI97001923A patent/MY132499A/en unknown
- 1997-05-05 CO CO97023872A patent/CO4650038A1/es unknown
- 1997-11-04 US US08/963,904 patent/US6211222B1/en not_active Expired - Fee Related
1998
- 1998-10-16 IS IS4871A patent/IS4871A/is unknown
- 1998-10-23 OA OA9800201A patent/OA10904A/en unknown
- 1998-11-02 NO NO19985095A patent/NO312959B1/no not_active IP Right Cessation
- 1998-11-23 BG BG102946A patent/BG64211B1/bg unknown
1999
- 1999-09-27 US US09/406,220 patent/US6127398A/en not_active Expired - Fee Related
2002
- 2002-11-08 CN CN02149950A patent/CN1422849A/zh active Pending

Also Published As

Publication number	Publication date
SK148298A3 (en)	2000-02-14
HK1019443A1 (en)	2000-02-11
WO1997042174A1 (en)	1997-11-13
CN1217714A (zh)	1999-05-26
EP0912521A1 (en)	1999-05-06
CA2252982A1 (en)	1997-11-13
CZ292825B6 (cs)	2003-12-17
IL126547A (en)	2003-03-12
CO4650038A1 (es)	1998-09-03
HRP970227A2 (en)	2000-12-31
EA002272B1 (ru)	2002-02-28
AP1147A (en)	2003-02-25
DZ2217A1 (fr)	2002-12-03
KR20000010751A (ko)	2000-02-25
AP2001002304A0 (en)	2001-12-31
AP1146A (en)	2003-02-25
AP9700975A0 (en)	1997-07-31
NO985095L (no)	1998-12-29
JP3148254B2 (ja)	2001-03-19
AP2001002294A0 (en)	2001-12-31
US6211222B1 (en)	2001-04-03
HN1997000046A (es)	1997-06-26
BG102946A (en)	1999-11-30
AU725576B2 (en)	2000-10-12
CN1112359C (zh)	2003-06-25
ZA973804B (en)	1998-11-02
NO985095D0 (no)	1998-11-02
UA65536C2 (en)	2004-04-15
TR199802202T2 (xx)	1999-02-22
AR006906A1 (es)	1999-09-29
ES2238079T3 (es)	2005-08-16
TNSN97070A1 (fr)	2005-03-15
ATE292626T1 (de)	2005-04-15
CZ349298A3 (cs)	1999-09-15
MA24158A1 (fr)	1997-12-31
EA199800882A1 (ru)	1999-06-24
NO312959B1 (no)	2002-07-22
NZ332240A (en)	2000-07-28
HUP9902459A2 (hu)	1999-11-29
JPH11508284A (ja)	1999-07-21
TW449585B (en)	2001-08-11
CA2389918A1 (en)	1997-11-13
UY24532A1 (es)	2000-09-29
US6127398A (en)	2000-10-03
CA2252982C (en)	2002-10-08
CN1422849A (zh)	2003-06-11
GT199700043A (es)	1998-10-02
HRP970227B1 (en)	2002-06-30
IL126547A0 (en)	1999-08-17
PE64598A1 (es)	1998-10-26
IL152083A0 (en)	2003-05-29
DE69732966T2 (de)	2005-09-08
HUP9902459A3 (en)	2001-10-29
YU16397A (sh)	1999-12-27
PL329836A1 (en)	1999-04-12
AU1937397A (en)	1997-11-26
MY132499A (en)	2007-10-31
BR9709051A (pt)	1999-08-03
EP0912521B1 (en)	2005-04-06
KR100339935B1 (ko)	2002-07-18
BG64211B1 (bg)	2004-05-31
DE69732966D1 (de)	2005-05-12
AP0102304A0 (en)	1997-11-03
ID16856A (id)	1997-11-13
OA10904A (en)	2001-10-11

Publication	Publication Date	Title
IS4871A (is)	1998-10-16	Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)
IS4979A (is)	1999-02-16	Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
IS4910A (is)	1998-11-27	Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
AU2002226911A1 (en)	2002-06-03	Indol derivative and their use as inhibitors of p38 kinase
FI950859A7 (fi)	1995-02-24	Arylideeni- ja heteroarylideeni-oksindolijohdannaiset tyrosiinikinaasi-inhibiittoreina
SI1475377T1 (sl)	2006-12-31	Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
AU5704594A (en)	1994-07-19	Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
HUP0102113A1 (hu)	2001-12-28	2-(2,6-Dioxo-piperidin-3-il)-izoindolinszármazékok, előállításuk és alkalmazásuk, mint a gyulladáskeltő citokinek inhibitorai
NO20000487L (no)	2000-03-31	Substituerte quinazolinderivater og anvendelse derav som tyrosin-kinase-inhibitorer
AU2001288374A1 (en)	2002-03-22	Substituted oxindole derivatives as tyrosine kinase inhibitors
AU3885900A (en)	2000-10-09	Inhibitors of the egf-receptor tyrosine kinase and their use
NO20015062L (no)	2001-10-18	Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
AU2955195A (en)	1996-02-09	Tumor necrosis factor receptor-ii-associated protein kinase and methods for its use
AU4501199A (en)	1999-12-20	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
MXPA02009550A (es)	2004-05-14	Derivados de pirano (2,3,c)imidazo(1,2-a]piridina para el tratamiento de trastornos gastrointestinales.
AU2876000A (en)	2000-08-29	Tyrosine kinase inhibitors and methods of using the same
GB0511267D0 (en)	2005-07-13	Indol derivatives and their use as kinase inhibitors
HK1057013A (en)	2004-03-12	Indazole derivatives as jnk inhibitors
AU2003200580A1 (en)	2003-05-01	Substituted pyrazoles as P38 kinase inhibitors
HK1079192A (en)	2006-03-31	Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors